Dasatinib

Generic Name: Dasatinib

Brand Names: Sprycel

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₆ClN_₇O_₂S

CAS Number: 302962-49-8

Unique Ingredient Identifier: X78UG0A0RN

Background: Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...

Indication: Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Dasatinib in Resectable Malignant Pleural Mesothelioma

Phase 1

Completed

Conditions: Malignant Pleural Mesothelioma

Interventions: Drug: Dasatinib

First Posted Date: 2008-04-03

Last Posted Date: 2022-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 56

Registration Number: NCT00652574

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

Not Applicable

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Dasatinib

First Posted Date: 2008-02-27

Last Posted Date: 2013-12-16

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 18

Registration Number: NCT00624585

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Immunoblastic Lymphoma
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Liver Carcinoma
Recurrent Adult T-Cell Leukemia/Lymphoma
Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma
Recurrent Grade 3 Follicular Lymphoma

Interventions: Drug: Dasatinib
Other: Pharmacological Study

First Posted Date: 2008-02-06

Last Posted Date: 2015-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 80

Registration Number: NCT00608361

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Hutchinson Regional Medical Center, Hutchinson, Kansas, United States
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States

and more 20 locations

A Phase I/Expansion Study of Dasatinib

Phase 1

Terminated

Conditions: Refractory Solid Tumors
Pancreatic Adenocarcinoma

Interventions: Drug: gemcitabine
Drug: dasatinib

First Posted Date: 2008-01-18

Last Posted Date: 2015-09-07

Lead Sponsor: Duke University

Target Recruit Count: 30

Registration Number: NCT00598091

Locations: 🇺🇸
UNC Lineberger, Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States

Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

Phase 2

Completed

Conditions: Recurrent Prostate Cancer
Hormone-resistant Prostate Cancer
Hormone-refractory Prostate Cancer
Adenocarcinoma of the Prostate
Prostate Cancer

Interventions: Drug: Dasatinib

First Posted Date: 2007-12-11

Last Posted Date: 2019-02-26

Lead Sponsor: University of California, Irvine

Target Recruit Count: 38

Registration Number: NCT00570700

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States
🇺🇸
St. Joseph Hospital, Orange, California, United States

and more 3 locations

Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: dasatinib

First Posted Date: 2007-12-10

Last Posted Date: 2016-01-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 22

Registration Number: NCT00570401

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumor

Interventions: Drug: dasatinib

First Posted Date: 2007-12-06

Last Posted Date: 2019-06-17

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 47

Registration Number: NCT00568750

Locations: 🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷
Centre Paul Strauss, Strasbourg, France
🇫🇷
Hopital Edouard Herriot - Lyon, Lyon, France

and more 15 locations

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

Phase 1

Completed

Conditions: Breast Cancer
Bone Metastases

Interventions: Drug: Dasatinib
Drug: Zoledronic Acid

First Posted Date: 2007-12-03

Last Posted Date: 2022-02-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00566618

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Dasatinib

First Posted Date: 2007-11-28

Last Posted Date: 2015-02-23

Lead Sponsor: Duke University

Target Recruit Count: 2

Registration Number: NCT00564876

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Recurrent Skin Cancer
Squamous Cell Carcinoma of the Skin
Stage 0 Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia

Interventions: Drug: dasatinib
Other: laboratory biomarker analysis

First Posted Date: 2007-11-26

Last Posted Date: 2015-06-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 7

Registration Number: NCT00563290

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy